The MHC locus and genetic susceptibility to autoimmune and infectious diseases.
Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. · 2017
Read The MHC locus and genetic susceptibility to autoimmune and infectious diseases. by Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5406920.txt.
Introduction
Vasiliki Matzaraki, Vinod Kumar, Cisca Wijmenga, and Alexandra Zhernakova review a key gene region and disease risk in a 2017 Genome Biology paper. The region, called the MHC or HLA locus, holds genes that show cell proteins to the immune system. Over the past fifty years, variants there have been named as top risk factors for many complex diseases, both autoimmune and infectious.
Fresh tools now let researchers scan the region densely, fill in missing variants, and test effects that only show when variants act together or in pairs. The review weighs what these gains reveal about variants shared across diseases and those tied to just one. It also frames a live question: whether germs help trigger autoimmune disease, and how these variants could settle the rival accounts.
Catalog record
| CREATOR | Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 96 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The MHC locus and genetic susceptibility to autoimmune and infectious diseases By Vasiliki Matzaraki, Vinod Kumar, Cisca Wijmenga, Alexandra Zhernakova Published in: Genome Biology DOI: 10.1186/s13059-017-1207-1 ABSTRACT In the past 50 years, variants in the major histocompatibility complex (MHC) locus, also known as the human leukocyte antigen (HLA), have been reported as major risk factors for complex diseases. Recent advances, including large genetic screens, imputation, and analyses of non-additive and epistatic effects, have contributed to a better understanding of the shared and specific roles of MHC variants in different diseases. We review these advances and discuss the relationships between MHC variants involved in autoimmune and infectious diseases. Further work in this area will help to distinguish between alternative hypotheses for the role of pathogens in autoimmune disease development. Electronic supplementary material The online version of this article (doi:10.1186/s13059-017-1207-1) contains supplementary material, which is available to authorized users. INTRODUCTION The major histocompatibility complex (MHC) locus, also known as the human leukocyte antigen (HLA) locus, spans around 4 Mbp on the short arm of chromosome 6 (6p21.3; Box 1). Molecules encoded by this region are involved in antigen presentation, inflammation regulation, the complement system, and the innate and adaptive immune responses, indicating the MHC’s importance in immune-mediated, autoimmune, and infectious diseases [1]. Over the past 50 years, polymorphisms in the MHC locus have been shown to influence many critical biological traits and individuals’ susceptibility to complex, autoimmune, and infectious diseases (Boxes 2 and 3). In addition to autoimmune and inflammatory diseases, the MHC has recently been found to play a role in some neurological disorders [2–6], implicating autoimmune components in these diseases. The genetic structure of the MHC is characterized by high levels of linkage disequilibrium (LD) compared to the rest of the genome, which means there are technical challenges in identifying MHC single nucleotide polymorphisms (SNPs), alleles, and amino acids. However, the recent availability of dense genotyping platforms, such as the custom-made Illumina Infinium SNP chip (Immunochip) [7], and of MHC reference panels has helped to fine-map the locus, improving our understanding of its disease associations and our ability to identify functional variants. In this review, we discuss recent advances in mapping susceptibility variants in the MHC, using autoimmune and infectious diseases as examples (Boxes 2 and 3). We also discuss the relationships between the MHC variants involved in both autoimmune and infectious diseases and offer insights into the MHC-associated immune responses underlying disease onset and pathogenesis. Finally, we discuss future directions for studying genetic variation in the MHC and how learning about the variation at this locus will aid understanding of disease pathogenesis. ADVANCES IN MAPPING SUSCEPTIBILITY VARIANTS IN THE MHC LOCUS Several computational and empirical challenges complicate the mapping of MHC susceptibility variants. One fundamental challenge is that the MHC has many sequence and structural variations [8], which differ between populations and complicate haplotype inference. Another is that high and extensive LD in the locus makes it difficult to identify causal and independent loci. Non-additive allelic effects in the MHC, and epistatic effects between the MHC and other loci, can also complicate inference of the underlying haplotype structure and disease susceptibility variants. In recent years, large volumes of sequencing data have made it possible to impute MHC variation on a wide scale, thereby improving our understanding of variability at this locus and of the haplotype structures and enabling reference panels to be created. The availability of accurate reference panels and a large number of genotyped individuals has allowed the identification of independent variants and improved our understanding of their contribution to disease heritability and pathways underlying disease biology [9, 10]. Advances in laboratory-based mapping of MHC variation Increased throughput, accuracy, and read length in next-generation sequencing (NGS) technologies, as well as the development of user-friendly bioinformatics tools, have enabled higher resolution MHC typing [11]. For instance, whole-genome sequencing (WGS) was successfully used to type HLA-A alleles at full resolution in 1070 healthy Japanese individuals [12] and to fully evaluate HLA-E variability in West African populations [13]. However, the main problem with MHC sequencing using current technologies is the relatively short read lengths, which limit the amount of allelic data that can be generated at a high resolution. Long-range PCR amplification approaches, such as the use of PacBio systems for single molecule real-time sequencing, significantly increase read-length and the resolution for typing MHC alleles [14]. In a comparison of MHC typing in an Indian population using sequence-specific primers, NGS (Roche/454) and single molecule sequencing (PacBio RS II) platforms, higher resolution typing was achieved for MHC class I (HLA-A, HLA-B, and HLA-C ) and class II genes (HLA-DRB1 and HLA-DQB1) using the PacBio platform, with a median read length of 2780 nucleotides [15]. High-density SNP panels, such as the Immunochip platform [7], which has been widely implemented in immunogenetics studies, are a cheaper, faster, and easier alternative to genotyping than direct MHC typing and NGS methods. The Immunochip contains a dense panel of SNPs from the MHC locus, which enables missing classic MHC variants to be inferred in silico, where the imputation is based on the haplotype structure present in large reference panels (Fig. 1). This fine-mapping approach has been used for several autoimmune and inflammatory diseases (Table 1) and for a few infectious diseases (Additional file 1), thereby allowing comprehensive interrogation of the MHC. Moreover, population-specific reference panels made by deep sequencing and used to impute genotypes allow identification of very rare variants and novel single-nucleotide variants in the human genome. This is illustrated by a recent study in which the authors first built a Han Chinese MHC-specific database by deep sequencing the region in 9946 patients with psoriasis and 10,689 healthy controls, and then used this reference panel to impute genotype data to fine-map psoriasis-associated variants [16]. Notably, functional variants in non-coding regions can be identified, as shown in a Japanese cohort of 1070 healthy individuals [12]. These variants would be impossible to discover using SNP microarrays or low coverage sequencing on the same sample size (Fig. 1, Table 1).Fig. 1Major histocompatibility complex imputation. A reference cohort of subjects for whom both genetic information and classic human leukocyte antigen (HLA) typing is available can be used to infer the missing (untyped) genotypes and amino acids in a discovery cohort. This allows imputed variants to be tested for their associations with a disease of interest. The figure shows imputation points to classic alleles associated with celiac disease risk in the MHC region on chromosome 6. Y tyrosine, S serine, Q glutamine, T threonine, R arginine, E glutamic acid Table 1Major histocompatibility complex (MHC) associations to autoimmune diseases, as described by fine-mapping studiesDiseaseClassic associated locusFine-mapping: top locusHLA class for top associationFine-mapping: independent associations at P < 5 × 10–8 HLA class for independent associationPopulationSample sizeReferenceRAShared epitope (HLA-DRB1 AA70-74)HLA-DRB1: AA 11, 13, 71, 74IIHLA-B AA 9IEuropean5018 individuals with seropositive RA, 14,974 unaffected controls[19]HLA-DPB1 AA 9IIHLA-DRB1: AA 11, 57, 74IIChinese, Korean2782 seropositive RA cases, 4315 controls[34]HLA-DRB1: AA 11, 71, 74IIHLA-DPB1 AA 84IIJapanese6244 cases, 23,731 controls[25]HLA-DOA (rs378352)IIHLA-B 40:02ICeDHLA DQ locus (DQ2, DQ8)HLA-DQA1: AA 25 and 47; HLA-DQB1: AA 57 and 74IIAA9 in HLA-DPβ1IIEuropean12,016 cases, 11,920 controls[35]rs2301226 (near HLA-DPB1 gene)IIHLA-B*08:01IHLA-B*39:06Irs1611710 (HLA-F)IPsHLA-Cw6 (HLA-C 0602)HLA-C*06:02IHLA-C*12:03IEuropean9247 patients, 13,589 controls[36]HLA-B amino acid 67IHLA-B amino acid 9IHLA-A amino acid position